The opioid crisis has shaped the national public health dialogue for some time now. A "call to action" is a strong and resounding cry from multiple disciplines. This piece intends to detail the nuts and bolts of prescribing medications used for the treatment of opioid use disorder. The underlying message here is that opioid use disorder is a chronic, treatable illness and physicians of all specialties have a responsibility to not turn a blind eye.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7023948 | PMC |
J Clin Psychiatry
January 2025
Division of Gastrointestinal and Liver Diseases, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California.
We compared substance use disorder (SUD) prevalence among adult inflammatory bowel disease (IBD) hospitalizations with non-IBD controls from the 2016-2018 National Inpatient Sample, assessing correlations with demographics, socioeconomic status, geographic regions, depression, and anxiety. The primary aim focused on SUD, defined as substance abuse or dependence (: F10-F19) excluding unspecified use or remission, among hospitalizations documenting IBD (Crohn's disease or ulcerative colitis; : K50-51) as one admitting diagnosis (IBD-D). The prevalence of SUD among hospitalizations with and without IBD was compared.
View Article and Find Full Text PDFDrugs Aging
January 2025
Center for Clinical Management Research, VA Ann Arbor Healthcare System, NCRC 016-308E, 2800 Plymouth Rd, Ann Arbor, MI, 48109, USA.
Background: Central nervous system (CNS)-active polypharmacy (defined as concurrent exposure to three or more antidepressant, antipsychotic, antiseizure, benzodiazepine, opioid, or nonbenzodiazepine benzodiazepine receptor agonists) is associated with significant potential harms in persons living with dementia (PLWD).We conducted a pilot trial to assess a patient nudge intervention's implementation feasibility and preliminary effectiveness to prompt deprescribing conversations between PLWD experiencing CNS-active polypharmacy and their primary care clinicians ("clinicians").
Methods: We used the electronic health record to identify PLWD prescribed CNS-active polypharmacy in primary care clinics from two health systems.
Support Care Cancer
January 2025
Department of Community Health Sciences, Cumming, School of Medicine, University of Calgary, 2500 University, Drive NW, Calgary, AB, T2N 1N4, Canada.
Int J Neuropsychopharmacol
January 2025
Department of Psychiatry and Psychology, Mayo Clinic; Rochester, Minnesota, USA.
Opioid use disorder (OUD) affects over 40 million people worldwide, creating significant social and economic burdens. Medication for opioid use disorder (MOUD) is often considered the primary treatment approach for OUD. MOUD, including methadone, buprenorphine, and naltrexone is effective for some, but its benefits may be limited by poor adherence to treatment recommendations.
View Article and Find Full Text PDFJ Thorac Dis
December 2024
Department of Anaesthesiology, Critical Care and Pain Medicine, University Hospital Mannheim, University of Heidelberg, Mannheim, Germany.
Background: Moderate to severe postoperative pain is common among patients following thoracotomy and serves as a risk factor for developing chronic post-thoracotomy pain (CPTP). This randomized controlled trial evaluated the effects of pre-emptively administered ketamine compared to placebo and standard care on both acute postoperative pain and CPTP.
Methods: Two hundred patients were enrolled in this prospective, randomized trial.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!